Merck KGaA Projects Forex-Adjusted Earnings Growth Up to 8% in 2025

Boost from Semiconductor Chemicals and Biotech Lab Demand / Reuters Merck KGaA, a leading German science and technology conglomerate, has unveiled an optimistic financial outlook, projecting forex-adjusted earnings growth of up to 8% for 2025. This forecast, driven by robust demand for semiconductor chemicals and laboratory equipment used in biotech drug production, underscores the company’s strategic positioning in high-growth sectors. The Darmstadt-based firm anticipates its earnings before interest, taxes, depreciation, and amortization (EBITDA), adjusted for special items, to range between $6.6 billion and $7.1 billion in 2025, building on the $6.5 billion recorded in 2024. This projection aligns closely with analyst expectations and signals a promising recovery following a challenging period. With its diversified portfolio spanning Healthcare, Life Science, and Electronics, Merck KGaA is capitalizing on global trends such as artificial intelligence and pharmaceutical innovati...